Carbohydrates and Blood Glucose: Key Concepts, Measurements, and Diabetes

Introduction to Carbohydrates

• Carbohydrates are hydrates of carbon or compounds with water molecules; they are the immediate and primary source of energy, especially glucose. Glucose is also known as blood glucose.
• Glucose readily undergoes glycolysis to produce ATP (energy).
• Functions of glucose include:
  • Energy production via glycolysis
  • Structural integrity to cell membranes
  • Involvement in a series of sugars linked on RBC membranes, contributing to antigenicity and blood type determination
• Carbohydrates are classified by the number of monomeric sugars:
  • Monosaccharides: e.g., D-glucose (most important), D-galactose, D-fructose
  • Disaccharides: e.g., Maltose (two glucose units), Sucrose (glucose + fructose), Lactose (glucose + galactose)
  • Polysaccharides: e.g., Starch (linear with branches in plants like corn), Glycogen (storage form of glucose; highly branched), Cellulose (insoluble fiber; not digestible by humans due to lack of cellulase), Inulin (fructose units; fiber; friendly to some diabetics; found in root bulbs like sweet potato)
• Dietary relevance and digestion:
  • Starch and glycogen provide energy storage and supply
  • Cellulose provides roughage and supports bowel movement (peristalsis)
  • Inulin is relatively diabetes-friendly due to its fructose composition
• Lactase deficiency leads to lactose intolerance; lactose is comprised of glucose + galactose and requires lactase for digestion
• Galactosemia
  • Defects in galactose metabolism (e.g., galactokinase or uridyl transferase) cause buildup of galactose
  • Screened using Guthrie test and Butler method
  • If galactose accumulates in blood, cataract formation is a risk
• Specimens for carbohydrate measurements include whole blood, plasma, serum; urine and CSF can also be tested in certain conditions (e.g., meningitis suspected via CSF glucose)
• Anthropological and clinical connections:
  • Glucose is the main energy source for many tissues
  • Glycocalyx and glycoproteins involve carbohydrates in membranes and blood group antigens

Carbohydrate Measurements and Clinical Significance

• Importance of carbohydrate measurements in diseases with abnormal carbohydrate metabolism: hypoglycemia and diabetes; lactose intolerance (galactosemia) screening
• Key measurement specimens: whole blood, plasma, serum; urine (Benedict-type tests historically), CSF (if meningitis suspected)
• Blood glucose as a clinical parameter is influenced by sample handling: prompt separation of clot, delay leads to glycolysis and falsely lowered glucose values; fluoride/iodoacetate recommended to inhibit glycolysis in collected samples

Glycolysis, Gluconeogenesis, and Other Pathways (Overview)

• Glycolysis: metabolism of glucose to pyruvate or lactate with ATP production
• Gluconeogenesis: formation of glucose-6-phosphate from non-carbohydrate sources; liver is the key organ
• Glycogenolysis: breakdown of glycogen to glucose; liver and muscles are key organs
• Glycogenesis: conversion of glucose to glycogen for storage; liver and muscles
• Lipogenesis: conversion of carbohydrates to fatty acids
• Lipolysis: breakdown of fat to fatty acids

Hormones Regulating Blood Glucose

• Insulin: the only hormone that lowers blood glucose
  • Mechanisms: inhibits glycogenolysis and gluconeogenesis in the liver; promotes glucose uptake by peripheral tissues
  • Produced by β-cells of the islets of Langerhans in the pancreas; secretion inhibited by low energy/dietary scarcity and during trauma with high epinephrine
  • Prohormone and marker: Proinsulin is the inactive precursor; active insulin is generated after cleavage of C-peptide from proinsulin
  • C-peptide: marker of endogenous insulin production; elevated C-peptide > $1.9 ext{ ng/mL}$ suggests endogenous hyperinsulinism; normal value around $1.2 ext{ ng/mL}$; C-peptide to insulin ratio ≈ $5:1$
• Glucagon: opposites insulin; increases glucose by stimulating glycogenolysis and gluconeogenesis in the liver; produced by α-cells
• Epinephrine: increases glucose via activation of adenylate cyclase → cAMP → protein kinase A → glycogenolysis; short-term glucose regulation
• Cortisol: increases blood glucose by promoting gluconeogenesis and protein deamination; inhibits peripheral glucose metabolism; long-term regulation; produced in adrenal cortex (fasciculata) under ACTH control
• Growth hormone: raises blood glucose by inhibiting glucose uptake and antagonizing insulin; produced by anterior pituitary; contributes to long-term glucose regulation
• Thyroid hormone: increases glucose by promoting glycogenolysis, enhancing insulin degradation, and promoting intestinal glucose absorption; produced by thyroid follicle cells
• Somatostatin: modulates and neutralizes actions of insulin and glucagon; produced by δ-cells of islets of Langerhans

Blood Glucose Determination: Normal Values and Specimen Handling

• Normal values (most sensitive methods):
  • Serum/plasma: $50 ext{ to } 110 ext{ mg/dL} ext{ (2.8 to 6.2 mmol/L)}$
  • Whole blood: about 10% lower than serum/plasma; $45 ext{ to } 100 ext{ mg/dL}$
  • CSF: $40 ext{ to } 70 ext{ mg/dL}$ (≈ 60–75% of serum/plasma level)
• Practical notes:
  • Prompt clot separation is essential; RBC glycolysis lowers serum glucose by ~5% per hour if clot contact is prolonged
  • For delays, use fluoride or iodoacetate (e.g., 2 mg NaF per mL of whole blood) to inhibit glycolysis; test within 48 hours at 4°C

Chemical and Enzymatic Methods for Glucose Determination

• Non-enzymatic (copper reduction methods): principle: glucose reduces cupric to cuprous; Cu2O formation; color complex with phosphomolybdenum blue
  • Folin–Wu method (often used on whole blood after deproteinization with tungstate to remove turbidity)
  • Somogy–Nelson method (uses zinc sulfate and barium hydroxide to deproteinize; Cu2O reacts with arsenomolybdate to form arsenomolybdenum blue; removes non-glucose reducing substances, NGRS)
  • Neocuproine method (adapted to automation; sample deproteinized; Cu2O reacts with neocuproine to form a yellow-orange complex)
  • Benedict’s method (modification of Folin–Wu; used for urine sugars)
  • Schafer–Hartmann titrimetric method (iodine oxidation; titration with thiosulfate)
  • Ferric reduction methods (glucose reduces ferricyanide to ferrocyanide; yellow ferrocyanide monitored; e.g., Hagedorn–Jensen with ferrocyanide ions; ferrocyanide is less reoxidizable by air than cupric ions)
  • Condensation methods (glucose condenses with aromatic amines): Dobowski/Dabowski methods; orthotoluidine and similar reagents; forms glycosylamine/Schiff base; highly specific nonenzymatic method; anthrone improves specificity but not usually performed in routine testing
• Enzymatic methods: widely used; fastest with small sample volumes; enzymes provide high specificity
  • Glucose oxidase method (GOx) with peroxidase; glucose + O2 → gluconic acid + H2O2; in presence of peroxidase, a chromogen is oxidized to a colored product
  • Common chromogens and their color outputs when using GOx–peroxidase coupling:
  • p-aminophenazone (PAP) → pink to red
  • o-dianisidine → orange
  • orthotoluidine → green
  • 1,5-dianthroline or similar → blue
  • iodide → purple
  • Interference: vitamin C can interfere with GOx-coupled reactions
  • Glucose oxidase is often paired with peroxidase and chromogen to yield a colorimetric readout
  • Polarographic method (Clark electrode): monitors oxygen consumption during glucose oxidation by enzyme; oxygen consumption before and after enzyme addition provides glucose amount
  • Hexokinase method (reference method): most specific
  • Step 1: Glucose + ATP + Mg2+ (hexokinase) → glucose-6-phosphate (G6P) + ADP
  • Step 2: G6P + NADP+ (via G6P dehydrogenase) → 6-phosogluconolactone + NADPH + H+
  • Magnesium acts as a cofactor
• Summary: enzymatic methods (especially hexokinase) are preferred for clinical glucose determinations due to specificity and reliability

Diabetes Mellitus: Overview and Pathophysiology

• Diabetes mellitus: group of diseases with elevated blood glucose due to deficient insulin action
• Classic clinical presentation: the three P’s
  • Polyuria: increased urine output (glucose acts as an osmotic diuretic)
  • Polydipsia: excessive thirst due to urine-induced dehydration
  • Polyphagia: excessive eating (glucose unavailable inside cells despite high plasma glucose)

Type 1 vs Type 2 Diabetes Mellitus: Characteristics and Pathophysiology

• Type 1 diabetes mellitus (insulin-dependent; often juvenile)

  • Age of onset: puberty or childhood
  • Body habitus: often emaciated
  • Prevalence: about 10 ext{-}20 ext{
    %} of diagnosed diabetics
  • Genetic predisposition: moderate; HLA associations present (e.g., HLA-DR3/DR4)
  • Pathophysiology: autoimmune destruction of pancreatic β-cells in the islets of Langerhans; T-lymphocyte infiltration; autoantibodies common: GAD-65, IA-2, ZnT8
  • Insulin: secretion falls to zero as β-cells are destroyed
  • Initial metabolic response: glycogenesis and lipolysis; liver increases glucose output via glycogenolysis and gluconeogenesis; adipose tissue increases lipolysis → elevated free fatty acids → ketone bodies; risk of diabetic ketoacidosis (DKA); glucose in blood leads to glycosuria and osmotic diuresis; potential dehydration and acidosis
  • Treatment: insulin therapy is necessary

• Type 2 diabetes mellitus (non-insulin-dependent; adult-onset)

  • Age of onset: usually after 35 years, gradual
  • Body habitus: often obese at onset; often associated with obesity and physical inactivity
  • Prevalence: about 80 ext{-}90 ext{
    %} of diagnosed diabetics
  • Genetic predisposition: strong; HLA association usually absent
  • Pathophysiology: insulin resistance in peripheral tissues (muscle, adipose, liver); impaired or defective insulin action; compensatory hyperinsulinemia early on; progressive β-cell dysfunction leading to decreased insulin secretion over time
  • Complications: vascular (microvascular and macrovascular); neuropathy; infections; higher risk of heart disease; retinopathy, nephropathy
  • Ketosis: ketosis is rare in type 2
  • Renal, ocular, vascular complications are common

Diagnostic Criteria and Tests for Diabetes Mellitus

• Screening and diagnostic tests for DM:
  • Fasting Blood Sugar (FBS): ≥ $126 ext{ mg/dL}$ on at least two occasions
  • 2-hour postprandial glucose: ≥ $200 ext{ mg/dL}$ during an oral glucose tolerance test (OGTT) or equivalent
  • Random (casual) plasma glucose: ≥ $200 ext{ mg/dL}$ with hyperglycemia symptoms
  • Oral glucose tolerance test (OGTT): 75 g glucose load; diagnostic values at 2 hours: ≥ $200 ext{ mg/dL}$; baseline glucose is obtained; samples at 30 min, 1 h, 1.5 h, and 2 h
  • Intravenous glucose tolerance test (IVGTT): used when malabsorption or post-surgery; 20% glucose solution given over 3 minutes; samples at 0, 3, 5, 10, 20, 30, 40, 60, 100 min; glucose disappearance constants k calculated from log glucose vs time; k < $1.2$ indicates diabetes mellitus
  • HbA1c (glycosylated hemoglobin): monitor long-term glucose control; normal range < 6 ext{%}; measurement methods include electrophoresis, isoelectric focusing, HPLC, spectrophotometry, and RIA
  • Fructosamine: monitor short-term glucose control; reflects glucose bound to proteins
  • Random Blood Sugar (RBS): normal range $45 ext{ to }100 ext{ mg/dL}$; no fasting required
• Gestational diabetes mellitus (GDM) criteria and testing:
  • Screening: 1-hour OGTT with 50 g glucose load; no fasting required
  • If ≥ 140 mg/dL: proceed to diagnostic 3-hour OGTT with 100 g glucose load; overnight fasting required
  • Diagnostic cutoff values: plasma glucose ≥ cutoff at 2 or more samples confirms GDM (e.g., 145 mg/dL for two or more samples)
• Other categories and special forms of diabetes:
  • MODY (maturity-onset diabetes of the young)
  • Latent autoimmune diabetes in adults (LADA)
  • Neonatal diabetes (occurs within first 6 months of life)
  • Type 3c diabetes (diabetes due to pancreatic disease or pancreatic resection)
• Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) categories per ADA:
  • IFG: FBS 110 to 125 mg/dL
  • IGT: 2-hour post-load glucose 140 to 199 mg/dL

Hypoglycemia: Definition, Causes, and Diagnosis

• Hypoglycemia: low plasma glucose with symptoms that improve after carbohydrate intake
• Classic threshold: overnight plasma glucose < $45 ext{ mg/dL}$; in some diagnostic contexts, plasma glucose < $40 ext{ mg/dL}$ with symptomatic relief after glucose (Whipple’s triad)
• Whipple’s triad:
  1) Hypoglycemic symptoms precipitated by fasting
  2) Plasma glucose < $40 ext{ mg/dL}$
  3) Symptom relief after ingestion of glucose

Glycogen Storage Diseases (GSDs)

• Von Gierke disease (GSD I): glucose-6-phosphatase deficiency in liver and kidney
  • Clinical features: hepatomegaly, lactic acidosis, hyperlipidemia, severe fasting hypoglycemia
• Memorize as part of abnormal glucose handling disorders

Causes of Abnormal Glucose Levels (Overview)

• Persistent hyperglycemia disorders:
  • Diabetes mellitus (types 1 and 2), adrenal cortical hyperactivity (Cushing’s syndrome), hyperthyroidism, acromegaly, obesity, adrenal cortical insufficiency (Addison’s disease), hypopituitarism, galactosemia, ectopic insulin production (tumors)
• Transient or stress-related hyperglycemia:
  • Pheochromocytoma, severe liver disease, acute stress/shock, convulsions, alcohol ingestion, drugs (e.g., certain anti-tuberculosis agents), glycogen storage diseases, functional hypoglycemia, hereditary fructose intolerance

Practical Connections and Clinical Implications

• Diabetes management hinges on understanding insulin action, insulin and C-peptide levels, and the insulin/glucagon balance with other hormones (epinephrine, cortisol, growth hormone, thyroid hormone)
• Diagnostic tests are chosen based on stability, specificity, and context (screening vs diagnostic vs gestational diabetes)
• Enzymatic methods (especially hexokinase) are preferred for accuracy; non-enzymatic chemical methods are useful historically or in resource-limited settings
• Hypoglycemia assessment uses Whipple’s triad to determine clinically significant episodes
• Awareness of GSDs is important in differential diagnosis of hypoglycemia and metabolic crises

Quick Reference Equations and Key Values

• Glycolysis and energy: $ext{Glucose} <br /> ightarrow ext{Pyruvate} + ext{ATP}$
• Gluconeogenesis (simplified): non-carbohydrate sources ⟶ $ext{Glucose-6-phosphate}$
• Glycogenolysis: $ext{Glycogen} <br /> ightarrow ext{Glucose}$
• Glycogenesis: $ext{Glucose} <br /> ightarrow ext{Glycogen}$
• Lipogenesis: $ext{Carbohydrates} <br /> ightarrow ext{Fatty acids}$
• Lipolysis: breakdown of fat to fatty acids
• Insulin action: promotes peripheral glucose uptake; inhibits hepatic glycogenolysis and gluconeogenesis
• Proinsulin → insulin + C-peptide (cleavage of C-peptide)
• C-peptide marker: elevated > $1.9 ext{ ng/mL}$ suggests hyperinsulinism; normal ≈ $1.2 ext{ ng/mL}$
• Glucagon: ↑ glucose via glycogenolysis and gluconeogenesis
• GOx method (enzymatic): ext{Glucose} + ext{O}2 ightarrow ext{Gluconic acid} + ext{H}2 ext{O}_2}; with peroxidase and chromogen → colored product
• Hexokinase method (reference):
  • $ext{Glucose} + ext{ATP} + ext{Mg}^{2+} <br /> ightarrow ext{Glucose-6-phosphate} + ext{ADP}$
  • $ext{G6P} + ext{NADP}^+ <br /> ightarrow ext{6-phosphogluconolactone} + ext{NADPH} + ext{H}^+$
• Diagnostic thresholds (summary):
  • FBS: $ext{FBS} <br /> ightarrow ext{DM if } ext{FBS} ext{≥ } 126 ext{ mg/dL on two occasions}$
  • 2-hr OGTT: $ext{≥ } 200 ext{ mg/dL}$ after 75 g load
  • Random glucose: $≥ 200 ext{ mg/dL}$ with symptoms
  • HbA1c: < 6 ext{%} normal; higher values indicate poor control
  • IFG: $FBS = 110–125 ext{ mg/dL}$; IGT: $2 ext{-hour post-load} = 140–199 ext{ mg/dL}$
  • GDM screening: 1-hour 50 g load; if ≥ 140 mg/dL proceed to 3-hour 100 g OGTT; diagnostic if ≥ cutoff in ≥ 2 samples
  • IVGTT: 20% glucose over 3 minutes; glucose disappearance constant k < 1.2 indicates DM
• Normal values (summary):
  • Serum/plasma: $50–110 ext{ mg/dL} ag*{(2.8–6.2 mmol/L)}$
  • Whole blood: ~10% lower: $45–100 ext{ mg/dL}$
  • CSF: $40–70 ext{ mg/dL}$ (60–75% of serum)